Related Experiment Video
Updated: May 13, 2026

Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis
Published on: March 20, 2021
The role of biomarkers in the future of drug development
Scott D Patterson1, Robert F Dubose
1Department of Molecular Sciences, Amgen, Inc., 1 Amgen Center Drive, MS 38-3-A Thousand Oaks, CA 91320, USA; . spatters@amgen.com.
Abstract:
Biomarkers are beginning to be used earlier in drug development, thus allowing the pharmacodynamic effects of targeted therapeutics to be explored before clinical signs and symptoms can be evaluated. This trend will continue and ultimately may enable pharmacodynamic biomarkers to be commonly used to determine therapeutic dosing based on these more accurate measures of human physiological responses. At the same time, biomarkers are also beginning to be used to determine which patients will be likely to respond to the therapeutic, thus avoiding administration to those who will not be likely to benefit. The strategy to achieve these aims and how this can lead to information that can be fed back into drug discovery is described in this perspective.
Related Concept Videos
Pharmacogenomics: Identification of New Drug Targets
Biopharmaceutical Factors Influencing Drug Product Design: Overview
Biopharmaceutics and Pharmacokinetics: Overview
Drug Discovery: Overview
Drug Products: Biologics, Biosimilars and Interchangeables
Measurement of Bioavailability: Pharmacodynamic Methods
